CIRM Supports Groundbreaking Gene Therapy for AML and MDS

Image source: Canva  The California Institute for Regenerative Medicine (CIRM) recently awarded $8 million to Rochelle Emery, MD, at Senti Bio to advance a clinical trial for a novel therapy targeting two forms of blood cancer, acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). About AML and MDS Both cancers have a five‑year survival rate … Continue reading CIRM Supports Groundbreaking Gene Therapy for AML and MDS